Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease

Stock Information for Aldeyra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aldeyra Therapeutics Inc.

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Attention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors: Grabar Law Office Is Investigating Claims on Your Behalf
Attention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors
Grabar Law Office Investigates Claims on Behalf of Shareholders of Aldeyra Therapeutics, Inc. (ALDX)
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.